(Q44323240)
Statements
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors (English)
T Conroy
J F Seitz
S Gourgou
A Hua
D Mery-Mignard